Needle-Free Diabetes Care Market Size, Share, Growth, Forecast 2034

Industry Perspective:

The global needle-free diabetes care market size  was worth around USD 13.10 Billion in 2024 and is predicted to grow to around USD 23.54 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 6.04% between 2025 and 2034. The report analyzes the global needle-free diabetes care market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the needle-free diabetes care industry.

Request Free Sample

Needle - Free Diabetes Care Market: Overview

Diabetes is a collection of metabolic illnesses in which a person's blood sugar levels are elevated due to insufficient insulin production, improper cell response to insulin, or both or neither of these factors. To diagnose a patient, blood samples are typically drawn from them. This technique can result in needle-stick injuries, leading to several infections and suffering. People are using non-invasive, needle-free diabetic products as a result. During the projected period, an expanding patient population with diabetes and a rising prevalence of type 1 diabetes are expected to propel market expansion.

Traditionally, patients with type 1 diabetes who need frequent glucose testing use needles, which raises the risk of infection and discomfort for people. The use of needle-free equipment reduces delivery discomfort and infection risk.

Therefore, it is anticipated that there will be an increase in demand for these devices during the forecast period. Additionally, the industry has been driven by rising demand and technological developments in pain-free drug transportation and self-administration. However, the high cost of the facility and worries about technical difficulties are the factors anticipated to restrain the market's expansion for needle-free diabetes care.

Request Free Sample

COVID-19 Impact:

In a best-case scenario, it may be assumed that the COVID-19 epidemic has positively affected the adoption of needle-free injection systems. The COVID-19 pandemic has favorably impacted the global needle-free diabetes care market. It has brought attention to the necessity for self-injectable devices and mass vaccinations since the pandemic outbreak began in December 2019. To develop a needle-free injection system for the disease, as the number of cases has increased across regions, most hand-free injection system players have invested in R&D and have formed partnerships & agreements with other business and governmental entities.

Key Insights

• As per the analysis shared by our research analyst, the global needle-free diabetes care market is estimated to grow annually at a CAGR of around 6.04% over the forecast period (2025-2034).
• Regarding revenue, the global needle-free diabetes care market size was valued at around USD 13.10 Billion in 2024 and is projected to reach USD 23.54 Billion by 2034.
• The needle-free diabetes care market is projected to grow at a significant rate due to rising diabetes prevalence, demand for painless monitoring and insulin delivery, and innovations in non-invasive glucose monitoring technologies.
• Based on Product Type, the Jet Injectors segment is expected to lead the global market.
• On the basis of Application, the Insulin Delivery segment is growing at a high rate and will continue to dominate the global market.
• Based on the End User, the Hospitals segment is projected to swipe the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Needle - Free Diabetes Care Market: Growth Drivers

Increasing diabetes prevalence drives global needle-free diabetes care market growth

Diabetes is anticipated to be the sixth most significant cause of death by 2030, according to the WHO. Stress, sedentary habits, poor diets, and obesity are the main diabetes risk factors. Physiological changes brought on by aging play a sizable role in diabetes risk. For instance, the International Diabetes Federation claims that the prevalence of diabetes rises with age. Therefore, those over 65 years old are thought to have the highest estimated risk of diabetes. Adults aged 20 to 24 had the lowest prevalence of diabetes (2.2% in 2021). Diabetes prevalence is at 24.0% among persons aged 75 to 79 as of 2021 and is expected to rise to 24.7% by 2045. According to these figures, most diabetes will significantly grow over the next 25 years in nations with substantial geriatric populations. Therefore, it is anticipated that the need for needles less diabetes management solutions will be driven by the growing elderly population and the population's increased exposure to leading risk factors.

Needle-Free Diabetes Care Market: Report Scope    

Needle Free Diabetes Care Market: Restraints

More people using traditional diabetes management tools restraints the market demand

Patients still favor conventional diabetes management strategies in various geographical areas. With their low cost and lack of information about linked devices and apps, many patients reject advanced platforms in favor of traditional blood glucose readers, glucose strips, insulin injections, prefilled syringes, and medication therapy. The limited knowledge for managing diabetes in various nations has also impacted the acceptance of cutting-edge technologies. The use of needle-less diabetes management has been negatively affected in Asia, the Middle East, and Africa due to low awareness, a lack of educated staff, and unfavorable/minimal reimbursements. The market expansion in China and India is also being constrained by the reliance on complementary traditional diabetes control techniques like herbal medications.

Needle-Free Diabetes Care Market: Segmentation

The global needle-free diabetes care market is segregated based on device types, treatment, application, end users, and region.

By treatment, the market is divided into oral insulin, inhaled insulin, insulin patch, and others. With its outstanding efficiency, the insulin patch segment was shown to have the fastest expanding market share in 2021. The significant growth rate can be ascribed to elements like the rising incidence of diabetes and growing public knowledge of sophisticated patch pumps. People with type 1 diabetes prefer insulin patch pumps since they do not need to carry an insulin infusion set. Patch pumps are chosen by older and working individuals because of their greater convenience.

Patch pumps are generally smaller, more discrete, and easier to use than conventional insulin pumps. These pumps are also more affordable than traditional insulin delivery methods, which boosts demand. Patch pumps use an adhesive coating to bond to the skin and need minimal supervision. These pumps typically come with a blood glucose monitoring system or a continuous glucose monitor.

Based on application, the market is divided into insulin delivery and others. The global needle-free diabetes care market's most popular application area in 2021 was insulin delivery. The enormous population with diabetes drives the demand for insulin delivery devices. Additionally, the widespread use of recently introduced inventive pen devices and portable pumps is being aided by the rising demand for sophisticated insulin delivery systems, which is anticipated to accelerate market expansion.

Recent Developments

• In May 2022, Endo International plc announced that its subsidiary Endo Ventures Limited (EVL) had acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.

Needle - Free Diabetes Care Market: Regional Landscape

Growing prevalence of diabetics likely to help North America dominate the global market

North America held a monopoly on the global needle-free diabetes care market in 2021. The significant market growth in North America is mainly due to the increased number of diabetics and the availability of technologically improved equipment. By 2025, there are likely to be 5 million Canadians living with diabetes, according to the Canadian Diabetes Association. Therefore, it is anticipated that the vast patient population suffering from diabetes and its rising prevalence will spur growth in this area.

Request Free Sample

The region's dominance in the international arena has been aided by a high level of awareness regarding the potential advantages of needle-free drug delivery devices. Additionally, the market is expanding due to the availability of highly developed healthcare facilities and significant R&D spending by government agencies and pharmaceutical corporations to treat diabetes.

Needle - Free Diabetes Care Market: Competitive Landscape 

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the needle-free diabetes care market on a global and regional basis.

Some of the main competitors dominating the global needle-free diabetes care market include -

• European Pharma Group
• Medical International Technology Inc.
• Antares Pharma Inc.
• Zogenix Inc.
• 3M Company
• Valeritas Inc.
• Endo International plc.
• INJEX Pharma AG
• Bioject Medical Technologies Inc.

The global Needle-Free Diabetes Care Market is segmented as follows:

By Devices Types

• Treatment Devices
• Diagnostic Devices

By Treatment

• Oral Insulin
• Inhaled Insulin
• Insulin Patch
• Others

By Application

• Insulin Delivery
• Other

By End Users

• Diagnostic Centers
• Hospitals & Clinics And Other

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of  the Middle East & Africa